IDEAS home Printed from https://ideas.repec.org/a/kap/jbuset/v94y2010i2p225-242.html
   My bibliography  Save this article

Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry?

Author

Listed:
  • Thomas Hemphill

Abstract

No abstract is available for this item.

Suggested Citation

  • Thomas Hemphill, 2010. "Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry?," Journal of Business Ethics, Springer, vol. 94(2), pages 225-242, June.
    • Handle: RePEc:kap:jbuset:v:94:y:2010:i:2:p:225-242
    DOI: 10.1007/s10551-009-0259-x
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10551-009-0259-x
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10551-009-0259-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Maitland, Ian, 2002. "Priceless Goods: How Should Life-Saving Drugs be Priced?," Business Ethics Quarterly, Cambridge University Press, vol. 12(4), pages 451-480, October.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Arzi Adbi & Ajay Bhaskarabhatla & Chirantan Chatterjee, 2020. "Stakeholder Orientation and Market Impact: Evidence from India," Journal of Business Ethics, Springer, vol. 161(2), pages 479-496, January.
    2. Helen LaVan & Lori S. Cook & Ivana Zilic, 2021. "An analysis of the ethical frameworks and financial outcomes of corporate social responsibility and business press reporting of US pharmaceutical companies," International Journal of Business Governance and Ethics, Inderscience Enterprises Ltd, vol. 15(3), pages 326-355.
    3. Eline Picavet & Marc Dooms & David Cassiman & Steven Simoens, 2011. "Drugs for rare diseases: Influence of orphan designation status on price," Applied Health Economics and Health Policy, Springer, vol. 9(4), pages 275-279, July.
    4. Marialuisa Saviano & Sergio Barile & Francesco Caputo & Mattia Lettieri & Stefania Zanda, 2019. "From Rare to Neglected Diseases: A Sustainable and Inclusive Healthcare Perspective for Reframing the Orphan Drugs Issue," Sustainability, MDPI, vol. 11(5), pages 1-21, March.
    5. Belousova, Olga A. & Groen, Aard J. & Ouendag, Aniek M., 2020. "Opportunities and barriers for innovation and entrepreneurship in orphan drug development," Technological Forecasting and Social Change, Elsevier, vol. 161(C).

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Juan Elegido, 2009. "The Just Price: Three Insights from the Salamanca School," Journal of Business Ethics, Springer, vol. 90(1), pages 29-46, November.
    2. N. D. Albers & A. O. Wren & T. L. Knotts & M. G. Chupp, 2021. "Consumer Perceptions and Pricing Practices for Weddings," Journal of Consumer Policy, Springer, vol. 44(3), pages 407-426, September.
    3. Lori Verstegen Ryan, 2006. "Foundation and Form of the Field of Business Ethics," Journal of Private Enterprise, The Association of Private Enterprise Education, vol. 22(Spring 20), pages 34-49.
    4. Alexei M. Marcoux, 2009. "Retrieving Business Ethics from Political Philosophy," Journal of Private Enterprise, The Association of Private Enterprise Education, vol. 24(Spring 20), pages 21-33.
    5. Juan Elegido, 2015. "The Just Price as the Price Obtainable in an Open Market," Journal of Business Ethics, Springer, vol. 130(3), pages 557-572, September.
    6. Michael Buckley, 2013. "A Constructivist Approach to Business Ethics," Journal of Business Ethics, Springer, vol. 117(4), pages 695-706, November.
    7. Alexei M. Marcoux, 2006. "The Concept of Business in Business Ethics," Journal of Private Enterprise, The Association of Private Enterprise Education, vol. 22(Spring 20), pages 50-67.
    8. James Huebner, 2014. "Moral Psychology and the Intuition that Pharmaceutical Companies Have a ‘Special’ Obligation to Society," Journal of Business Ethics, Springer, vol. 122(3), pages 501-510, July.
    9. Arzi Adbi & Ajay Bhaskarabhatla & Chirantan Chatterjee, 2020. "Stakeholder Orientation and Market Impact: Evidence from India," Journal of Business Ethics, Springer, vol. 161(2), pages 479-496, January.
    10. Edward Balotsky, 2009. "Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries," Journal of Business Ethics, Springer, vol. 84(1), pages 75-88, January.
    11. Wade M. Chumney & David Wasieleski & E Günter Schumacher, 2017. "The conflict between U.S. patent protection and technological innovation," Post-Print hal-01768893, HAL.
    12. Alan Singer, 2010. "Integrating Ethics and Strategy: A Pragmatic Approach," Journal of Business Ethics, Springer, vol. 92(4), pages 479-491, April.
    13. Bénédicte Bourcier-Béquaert & Loréa Baïada-Hirèche & Anne Sachet-Milliat, 2022. "Cure or Sell: How Do Pharmaceutical Industry Marketers Combine Their Dual Mission? An Approach Using Moral Dissonance," Journal of Business Ethics, Springer, vol. 175(3), pages 555-581, January.
    14. Thomas Carson, 2013. "Free Exchange for Mutual Benefit: Sweatshops and Maitland’s “Classical Liberal Standard”," Journal of Business Ethics, Springer, vol. 112(1), pages 127-135, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:kap:jbuset:v:94:y:2010:i:2:p:225-242. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.